Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Fundamental Analysis

NASDAQ:MLTX - Nasdaq - KY61559X1045 - Common Stock - Currency: USD

48.07  -0.76 (-1.56%)

Fundamental Rating

2

Overall MLTX gets a fundamental rating of 2 out of 10. We evaluated MLTX against 558 industry peers in the Biotechnology industry. The financial health of MLTX is average, but there are quite some concerns on its profitability. MLTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MLTX had negative earnings in the past year.
In the past year MLTX has reported a negative cash flow from operations.
In the past 5 years MLTX always reported negative net income.
In the past 5 years MLTX always reported negative operating cash flow.
MLTX Yearly Net Income VS EBIT VS OCF VS FCFMLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a decent Return On Assets value of -28.40%, MLTX is doing good in the industry, outperforming 69.00% of the companies in the same industry.
MLTX's Return On Equity of -35.63% is fine compared to the rest of the industry. MLTX outperforms 73.66% of its industry peers.
Industry RankSector Rank
ROA -28.4%
ROE -35.63%
ROIC N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLTX Yearly ROA, ROE, ROICMLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

MLTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLTX Yearly Profit, Operating, Gross MarginsMLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, MLTX has more shares outstanding
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLTX Yearly Shares OutstandingMLTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
MLTX Yearly Total Debt VS Total AssetsMLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

MLTX has an Altman-Z score of 17.41. This indicates that MLTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MLTX (17.41) is better than 92.11% of its industry peers.
MLTX has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MLTX (0.18) is worse than 69.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z 17.41
ROIC/WACCN/A
WACCN/A
MLTX Yearly LT Debt VS Equity VS FCFMLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 21.11 indicates that MLTX has no problem at all paying its short term obligations.
MLTX has a Current ratio of 21.11. This is amongst the best in the industry. MLTX outperforms 94.27% of its industry peers.
MLTX has a Quick Ratio of 21.11. This indicates that MLTX is financially healthy and has no problem in meeting its short term obligations.
MLTX has a better Quick ratio (21.11) than 94.27% of its industry peers.
Industry RankSector Rank
Current Ratio 21.11
Quick Ratio 21.11
MLTX Yearly Current Assets VS Current LiabilitesMLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MLTX have decreased strongly by -206.67% in the last year.
EPS 1Y (TTM)-206.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MLTX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-56.75%
EPS Next 2Y-38.22%
EPS Next 3Y-27.44%
EPS Next 5Y27.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLTX Yearly Revenue VS EstimatesMLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
MLTX Yearly EPS VS EstimatesMLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLTX Price Earnings VS Forward Price EarningsMLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLTX Per share dataMLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

MLTX's earnings are expected to decrease with -27.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.22%
EPS Next 3Y-27.44%

More info and screens

0

5. Dividend

5.1 Amount

MLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (6/6/2025, 11:09:03 AM)

48.07

-0.76 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners103.64%
Inst Owner Change-4.7%
Ins Owners10.71%
Ins Owner Change2.27%
Market Cap3.09B
Analysts87.27
Price Target77.78 (61.81%)
Short Float %11.24%
Short Ratio14.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.11%
Min EPS beat(2)-18.11%
Max EPS beat(2)17.89%
EPS beat(4)1
Avg EPS beat(4)-16.06%
Min EPS beat(4)-37.92%
Max EPS beat(4)17.89%
EPS beat(8)4
Avg EPS beat(8)1.34%
EPS beat(12)8
Avg EPS beat(12)8.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.44%
PT rev (3m)-3.81%
EPS NQ rev (1m)6.36%
EPS NQ rev (3m)-10.32%
EPS NY rev (1m)3.92%
EPS NY rev (3m)-9.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 7.57
EV/EBITDA N/A
EPS(TTM)-2.3
EYN/A
EPS(NY)-3.61
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0
BVpS6.35
TBVpS6.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.4%
ROE -35.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.11
Quick Ratio 21.11
Altman-Z 17.41
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)797.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-206.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.36%
EPS Next Y-56.75%
EPS Next 2Y-38.22%
EPS Next 3Y-27.44%
EPS Next 5Y27.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-179.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-44.76%
EBIT Next 3Y-32.26%
EBIT Next 5YN/A
FCF growth 1Y-176.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-175.59%
OCF growth 3YN/A
OCF growth 5YN/A